Innovative
Therapeutics for
Better Health
Because Life
Shouldn't Have to
Wait for Migraines
Our Lead Product Candidate
STS101
Dihydroergotamine (DHE) Nasal Powder
Learn More
Clinical Trials
SUMMIT™ Trial
Enrollment Complete
Learn More
Press Releases
Dec 20, 2022
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
Read More
Nov 24, 2022
Satsuma Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
Read More
